SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 5

Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population

Levent YOLERİ
Peyker TEMİZ
Aylin TÜREL ERMERTCAN
Murat YAMAN
Mustafa Kürşat EVRENOS
Fethi Sırrı ÇAM
Pages
973–979
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This is the firststudy from our region evaluating the prognostic value of clinical stage and necessity of adjuvant treatment with the presence of BRAFand NRAS mutations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Malignant melanoma is the most common cause of death due to skin cancers.
📊
Key Findings & Data:In this study, we analyzed the frequency of BRAF and NRAS gene mutationsand investigated their association with clinicopathological features of melanomas in the Turkish population.Materials and methods: 65 primary cutaneous melanoma were included in the study.
💡
Conclusion & Impact:This is the firststudy from our region evaluating the prognostic value of clinical stage and necessity of adjuvant treatment with the presence of BRAFand NRAS mutations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Malignant melanoma is the most common cause of death due to skin cancers. The most common mutations in RAFRAS pathway from tumor oncogenes are BRAF and NRAS. In this study, we analyzed the frequency of BRAF and NRAS gene mutationsand investigated their association with clinicopathological features of melanomas in the Turkish population.Materials and methods: 65 primary cutaneous melanoma were included in the study. The mutations were evaluated with real-time PCRbased PCR-array through allele-specific amplification, and the results were correlated with various clinicopathological characteristics.Results: 52.3% of the patients were female and 47.7% were male. The mean age of the patients with a mutation was lower than thosewithout mutation. 16 patients had BRAF mutation. 12 patients had NRAS mutation. NRAS mutation was statistically more common inmen (P = 0.036). The number of mitoses increased with the increase of the tumor thickness (P = 0.003). There was more mitosis in thepresence of ulceration (P = 0.05). A total of 41.7% of NRAS mutations had adjuvant chemotherapy.Conclusion: We found lower mutation rate when compared to regional studies. NRAS mutation was common in men. This is the firststudy from our region evaluating the prognostic value of clinical stage and necessity of adjuvant treatment with the presence of BRAFand NRAS mutations.

🔖

Cite This Article

YOLERİ, L., TEMİZ, P., ERMERTCAN, A. T., YAMAN, M., EVRENOS, M. K., ÇAM, F. S. (2022). Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 5, 973–979. https://ajindex.com/articles/610165

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Timar J, Vizkeleti L, Doma V, Barbai T, Raso E. Genetic progression of malignant melanoma. Cancer Metastasis Rev 2016; 35: 93-107.
  2. Yilmaz I, Gamsizkan M, Kucukodaci Z, Berber U, Demirel D, Haholu A, Narli, G. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population. Indian J Pathol Microbiol 2015; 58: 279-284.
  3. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE. et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
  4. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346.
  5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W. et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
  6. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, Shih W, Gorski DH. et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005; 200: 362-370.
  7. Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011; 5: 124-36.
  8. Balch CM, Soong, S-J., Thompson, J. F. The natural history of melanoma and factors predicting outcome. In: J. F. DLM, & B. B. R. Kroon, editor. Textbook of melanoma. London: Taylor & Francis Group; 2004. pp. 181-199.
  9. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24: 879-97.
  10. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M. et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012; 7: e35309. Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM. et al. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer 2014; 50: 2668-2676.
  11. Yaman B, Akalin T, Kandiloglu G. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Am J Dermatopathol 2015; 37: 389-397.
  12. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, Lundeberg J